Beskrivning
| Land | Finland |
|---|---|
| Sektor | Hälsovård |
| Industri | Bioteknik |
FIT Biotech Oy
Company release 14.12.2018 at 09:00 AM EET
FIT Biotech's financial calendar and Annual General Meeting in 2019
During the year 2019, FIT Biotech Oy will publish the Financial Statement release 2018 and Half Year Financial Report 2019 as follows:
- Financial Statement Release 2018: Thursday 28 February 2019
- Half Year Financial Report 1-6/2019: Thursday 5 September 2019
The Annual Report 2018 will be available on FIT Biotech's home pages (www.fitbiotech.fi) during the week 12/2019.
Annual General Meeting is scheduled for Friday 12 April 2019. The Board of Directors of the company will convene the meeting.
FIT BIOTECH OY
Board of Directors
For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
FIT Biotech in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies its GTU® technology in its development projects, which at the time include gene-based treatments, genetic vaccines and research collaboration. Application areas include cancer (gene therapy) and infectious diseases such as HIV.
FIT Biotech K-shares are listed on the First North Finland market maintained by Nasdaq Helsinki Ltd.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
www.fitbiotech.com
--
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via Globenewswire